# Pre-Operative Window of ET to Inform RT Decisions (POWER II)

> **NCT06507618** · PHASE3 · RECRUITING · sponsor: **University of Virginia** · enrollment: 354 (estimated)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Tamoxifen, Letrozole, Anastrozole, or Exemestane

## Key facts

- **NCT ID:** NCT06507618
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2029-06-30
- **Final completion:** 2034-03-01
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507618, "Pre-Operative Window of ET to Inform RT Decisions (POWER II)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06507618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*